Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
SRPT Sarepta Therapeutics, Inc. daily Stock Chart
Sarepta Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.83 Insider Own7.20% Shs Outstand45.27M Perf Week43.46%
Market Cap1.69B Forward P/E- EPS next Y-3.71 Insider Trans0.00% Shs Float41.79M Perf Month48.41%
Income-199.80M PEG- EPS next Q-1.18 Inst Own62.30% Short Float22.03% Perf Quarter1.94%
Sales0.03M P/S62707.34 EPS this Y-2.40% Inst Trans4.12% Short Ratio4.35 Perf Half Y49.90%
Book/sh2.96 P/B12.64 EPS next Y24.00% ROA-83.80% Target Price46.75 Perf Year122.49%
Cash/sh2.21 P/C16.95 EPS next 5Y-0.20% ROE-108.40% 52W Range11.33 - 41.97 Perf YTD158.47%
Dividend- P/FCF- EPS past 5Y-15.90% ROI-53.10% 52W High-10.89% Beta0.80
Dividend %- Quick Ratio3.20 Sales past 5Y-11.10% Gross Margin- 52W Low230.10% ATR2.36
Employees204 Current Ratio3.20 Sales Q/Q- Oper. Margin- RSI (14)72.15 Volatility8.74% 6.95%
OptionableYes Debt/Eq0.19 EPS Q/Q-76.10% Profit Margin- Rel Volume0.48 Prev Close37.49
ShortableYes LT Debt/Eq0.14 EarningsNov 05 BMO Payout- Avg Volume2.11M Price37.40
Recom1.90 SMA2034.64% SMA5020.36% SMA20046.62% Volume1,007,848 Change-0.24%
Oct-23-15Resumed BofA/Merrill Buy
Oct-23-15Initiated Jefferies Hold $28
Oct-02-15Reiterated Needham Buy $38 → $55
Aug-26-15Reiterated ROTH Capital Buy $50 → $45
Aug-26-15Reiterated ROTH Capital Buy $45 → $50
Aug-24-15Upgrade Piper Jaffray Neutral → Overweight $28 → $48
Aug-07-15Downgrade Sun Trust Rbsn Humphrey Buy → Neutral
May-22-15Reiterated WBB Securities Strong Buy $25 → $35
May-21-15Downgrade BofA/Merrill Buy → Neutral
May-20-15Upgrade Sun Trust Rbsn Humphrey Neutral → Buy $14 → $33
May-20-15Upgrade Canaccord Genuity Hold → Buy $16 → $30
May-20-15Reiterated Wedbush Neutral $16 → $25
May-20-15Reiterated ROTH Capital Buy $22 → $45
May-20-15Reiterated RBC Capital Mkts Sector Perform $15 → $20
May-06-15Upgrade Robert W. Baird Neutral → Outperform $16 → $20
Mar-02-15Reiterated Needham Buy $52 → $38
Jan-23-15Initiated RBC Capital Mkts Sector Perform $15
Nov-26-14Upgrade WBB Securities Buy → Strong Buy $25 → $25
Oct-28-14Downgrade Robert W. Baird Outperform → Neutral $53 → $21
Aug-01-14Initiated Oppenheimer Outperform $45
Nov-28-15 06:56AM  Should You Buy OneBeacon Insurance Group, Ltd. (OB)? at Insider Monkey
12:01AM  [$$] Follow Up: Rival's Woes Bode Well for Sarepta at
Nov-25-15 02:52PM  Why this company's $700 million bet could come up short at
02:34PM  FDA Panel Seen As Bad For BioMarin, Good For Sarepta at Investor's Business Daily
02:22PM  Doubts about BioMarin drug
01:30PM  BioMarin's (BMRN) Kyndrisa Fails to Impress FDA Panel
11:55AM  Heres what former Sarepta CEO Chris Garabedian had to say about BioMarins drug panel at
11:05AM  Sarepta Therapeutics: Discretion Is the Better Part of Valor at Motley Fool
10:06AM  BioMarin: So You're Saying There's a Chance? at
07:26AM  Is Air Methods Corp (AIRM) A Good Stock To Buy? at Insider Monkey
06:49AM  BioMarin's Duchenne Drug Is Done, Sarepta Survives but Faces Challenge at TheStreet
Nov-24-15 09:35PM  Sarepta Rises 5.3%, Helping XBIs Small-Cap Stocks
06:41PM  BioMarin Drug's Future In Doubt After FDA Panel Vote at Investor's Business Daily
05:16PM  FDA panel: BioMarin muscle wastage drug data not persuasive Reuters
04:23PM  BioMarin Gets Unfavorable View From Panel on Duchenne Drug at Bloomberg
12:25PM  Heres the latest on todays FDA review of BioMarins Duchenne drug at
10:27AM  Sarepta Therapeutics, Inc. Value Analysis (NASDAQ:SRPT) : November 24, 2015
07:35AM  The first drug for Duchenne will be reviewed at the FDA today: Why it matters at
Nov-23-15 03:22PM  BioMarin's DMD Drug Faces Obstacles Tomorrow at Motley Fool +11.06%
02:40PM  BioMarin: 'Drisapersen Doesn't Work and Causes Harm,' Baird Says at
12:47PM  IBB Leads Biotech ETFs with Rise of 3.1%
12:40PM  BioMarin Down on FDA's Briefing Document on Kyndrisa
08:23AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : November 23, 2015
Nov-21-15 08:15AM  KaloBios, Valeant Lead Week's 5 Top Drug Stock Gainers at Investor's Business Daily
12:01AM  This Weekend's Barron's: Profiles of 16 Women Who Have Made the Top 100 Women Advisors for 10 Years ~ Biotech Battle Between Sarepta and Biomarin at
12:01AM  [$$] Biotech's Biggest Battle at
Nov-20-15 02:36PM  3 Stocks to Buy on Big Volume at TheStreet +27.96%
12:56PM  BioMarin's Pain is Sarepta's Gain, Right? Maybe Not. at
12:15PM  Why Sarepta Therapeutics Inc Is Soaring Today at Motley Fool
12:09PM  Duchenne moms say FDA documents widen the divide between drugs by BioMarin, Sarepta at
11:28AM  Google eyes the clouds, wealth gap persists, and more controversy for Citi
10:36AM  This May be Biotechs Next Huge Winner
10:19AM  Here's Why Sarepta Is Skyrocketing While BioMarin Is Falling
09:35AM  4 Biopharma and Pharmaceutical Stocks With Game-Changing Catalysts Coming at 24/7 Wall St.
08:33AM  BioMarin Duchenne Drug Receives Harsh Review From FDA at TheStreet
Nov-19-15 05:24PM  The biggest event in biotech this year -5.95%
01:46PM  FDA Advisory Committee Sets Up Big Biotech Moves at The Wall Street Journal
11:42AM  These Biotech Stocks Could Move on BioMarin's Duchenne Drug FDA Panel at TheStreet
07:45AM  Sarepta draws bullish call spread
Nov-18-15 12:40PM  Sarepta's Long-Term Phase IIb Data on Eteplirsen Published
11:35AM  Sarepta Could Crush It, Even with a Broken FDA
06:00AM  How to Prepare for BioMarin's (and Biotech's) Biggest Event of 2015 at TheStreet
Nov-17-15 11:12AM  [$$] Sarepta Cites Positive Muscular Dystrophy Drug Trial Results at The Wall Street Journal +5.24%
08:43AM  Sarepta Therapeutics Announces Publication of Positive Long-Term Safety and Efficacy Data for Eteplirsen in the Annals of Neurology Business Wire
Nov-13-15 03:28PM  Competing for a cure: Sarepta Therapeutics CEO
03:27PM  The search for rare disease cure
Nov-06-15 12:10PM  Sarepta Posts Wider-than-Expected Loss in Q3, Shares Down
10:21AM  False tweets now on SECs fraud radar at MarketWatch
08:25AM  Wall Street Hammered These 3 Biotech Stocks: Are They Really Screaming Buys? at 24/7 Wall St.
05:20AM  Edited Transcript of SRPT earnings conference call or presentation 5-Nov-15 1:00pm GMT
Nov-05-15 06:43PM  Fraudulent Stock Tweets Result In Civil And Criminal Charges For Scottish Man at Forbes
12:38PM  Experts say Sarepta has a clear edge over BioMarin in Duchenne drug battle at
08:05AM  Sarepta Therapeutics reports 3Q loss
08:00AM  Sarepta Therapeutics Inc Earnings Call scheduled for 8:00 am ET today
07:13AM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or
07:07AM  Q3 2015 Sarepta Therapeutics Inc Earnings Release - Before Market Open
07:00AM  Sarepta Therapeutics Announces Third Quarter 2015 Financial Results and Recent Corporate Developments Business Wire
Nov-03-15 12:50PM  In the footsteps of Sarepta: 7 other drugmakers working on Duchenne at
Nov-02-15 05:17PM  Will Geron (GERN) Post a Wider-than-Expected Loss in Q3? +6.65%
05:04PM  Will Aerie (AERI) Post a Wider-Than-Expected Loss in Q3?
04:42PM  What to Expect from Radius (RDUS) This Earnings Season
04:40PM  Can Celldex (CLDX) Surprise Estimates in Q3 Earnings?
Nov-01-15 03:40PM  BioMarin Pharmaceutical Inc. Earnings: Pushing Toward Profitability at Motley Fool
Oct-30-15 05:08PM  Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire
01:40PM  Will Prothena (PRTA) Miss Estimates This Earnings Season?
01:35PM  Will Arena's (ARNA) Q3 Loss be Narrower-than-Expected?
08:19AM  Why biotech could be on the verge of a rebound
Oct-28-15 09:58AM  Gene Therapy Could Treat Debilitating Form Of Muscular Dystrophy at Forbes
Oct-27-15 04:12PM  Can Keryx (KERX) Surprise Investors This Earnings Season?
08:30AM  Sarepta Therapeutics to Announce Third Quarter 2015 Financial Results and Recent Corporate Developments on November 5, 2015 Business Wire
Oct-21-15 01:02PM  The Biotech Scramble for Big Money in Muscular Dystrophy Drugs at Bloomberg
Oct-20-15 04:30PM  Ultragenyx (RARE) Reports Positive Interim Data on UX007
Oct-18-15 10:38AM  3 Biotech Stocks We're Ready to Sell at Motley Fool
09:04AM  Is Sarepta Therapeutics Worth the Risk? at Motley Fool
Oct-16-15 01:21PM  Duchenne mom on delay in Sarepta drug review: Eight weeks is not nothing at
11:06AM  Radius Continued to Fall despite Positive Data on Osteoporosis
06:50AM  Biotech Stock Mailbag: New Sarepta Risk, Zafgen Patient Death, Bluebird Gene Therapy Update at TheStreet
Oct-15-15 06:54PM  PTC Stock Seesaws On Muscular Dystrophy Drug Data at Investor's Business Daily
02:50PM  Sarepta Down, Eteplirsen Likely to Face FDA Panel in Jan
12:31PM  Sarepta Is Now Enormously Compelling
08:00AM  New ETF tracks breakthroughs in cancer treatments
Oct-14-15 01:01PM  Sareptas competitor on Duchenne drug could get a two-month head start on sales at -11.78%
12:43PM  Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular Dystrophy Business Wire
12:20PM  Heres Why These Five Stocks Are Plunging Today at Insider Monkey
11:47AM  BioMarin Secures FDA Panel Date for Duchenne Drug but Where is Sarepta? (Update) at TheStreet
Oct-13-15 09:45AM  Sarepta Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : October 13, 2015 -5.40%
06:00AM  Jim Cramer's Top Takeaways: Helen of Troy, BioMarin, Energy Transfer Partners at TheStreet
Oct-09-15 11:19AM  Sarepta Therapeutics Announces Closing of $127 Million Public Offering of Common Stock Business Wire
Oct-06-15 05:18PM  SAREPTA THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and -9.07%
12:10PM  Why Shares of Sarepta Therapeutics Inc Are Falling Today at Motley Fool
10:57AM  Sarepta Therapeutics (SRPT) Stock Falls After Pricing Secondary Offering at TheStreet
10:35AM  Why Sarepta Deserves Praise for Capital Raise Despite Stock Drop at 24/7 Wall St.
09:17AM  Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race? at Motley Fool
09:15AM  Sarepta Therapeutics Announces Pricing of $127 Million Public Offering of Common Stock Business Wire
Oct-05-15 04:41PM  Sarepta Therapeutics Announces Proposed Public Offering of Common Stock Business Wire +5.56%
Oct-03-15 01:20PM  Sarepta's Less-Than-Perfect Data at Motley Fool
Oct-02-15 05:44PM  Sarepta: New Data Should Boost Stock Even Further at
03:10PM  Sarepta Unveils New Phase IIb Eteplirsen Data, Shares Soar
12:29PM  ETFs with exposure to Sarepta Therapeutics, Inc. : October 2, 2015
Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Its lead product candidate is Eteplirsen, an antisense phosphorodiamidate morpholino oligomer therapeutic, which is in Phase III clinical development stage for the treatment of individuals with Duchenne muscular dystrophy (DMD), a rare genetic muscle-wasting disease caused by the absence of dystrophin. The company also focuses on developing therapeutics for the treatment of drug-resistant bacteria, Becker muscular dystrophy, progeria, adult onset pompe, lupus and graft-versus-host diseases; and other rare, genetic, anti-infective, neuromuscular, and central nervous system diseases. The company is also involved in developing treatments that are in Phase I clinical trials for infectious diseases, including AVI-7288 for Marburg virus; and AVI-7100 for H1N1 influenza virus. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kaye Edward M. MDSVP & Chief Medical OfficerFeb 27Buy11.828009,4521,311Mar 03 06:48 PM
Christopher Nishan GarabedianPresident and CEOFeb 27Buy11.828009,45229,552Mar 03 06:47 PM